According to the new market research report by IndustryARC titled “ [FURL=https://www.industryarc.com/PressRelease/352/Prostate-Specific-Antigen-Testing-Market-Research-Analysis.html]Prostate Specific Antigen (PSA) Testing Market[/FURL] : By Type (Free Prostate-Specific Antigen Test, Complex Prostate Specific Antigen Test, Prostate Specific Antigen Reverse Transcription Polymerase Chain Reaction Test); By Assays (Radioimmunoassay, Enzyme Immunoassay); By Geography - Forecast (2018-2023)”, the market is expected to reach a revenue of $2888.96 million by 2023 at a CAGR of 4.14% during the forecast period. Europe has a larger share of the Prostate Specific Antigen (PSA) Market. It is expected to reach $1238.8 Million by 2023 with a CAGR of 3.37% in the coming years. The growth of PSA testing procedures in North America is attributed to the focus on healthcare. In Mexico, prostate-specific antigen testing has been implemented in many of its clinics and laboratories. A number of men suffer from prostate cancer in this region. Hence, the need for new diagnostic tools and testing methods has spurred the growth of the Prostate Specific Antigen (PSA) Testing Market during the forecast period. In Mexico, prostate-specific antigen testing has been implemented in many of its clinics and laboratories. A number of men suffer from prostate cancer in this region. Hence, the need for new diagnostic tools and testing methods has spurred the growth of the Prostate Specific Antigen (PSA) Testing Market during the forecast period.
Free Prostate-Specific Antigen Test, also known as FPSA is a major PSA blood test. It uses a blood sample of a man to carry out the test. FPSA is described as the amount of PSA in the blood that circulates freely. The test only measures the FPSA which is not bounded to the proteins in the blood. It can predict the risk of prostate cancer in men.
A prostate-specific antigen test can detect fast-growing cancer at an early stage. This stops cancer from spreading. Regular PSA tests can be helpful for men. This factor drives the growth of the market. slow growing cancers and potentially lethal cancers. Rising cases of Prostate cancer also drive the demand for PSA Testing.
The mortality rate has reduced to 23.8 from 23.6. This indicates that the PSA test is very effective in determining prostate cancer.
Screening approaches in the US and Europe have reduced the mortality rate of prostate cancer in a faster way.
Key players of the Prostate Specific Antigen (PSA) Testing Market:
Quest Diagnostics Inc., Neo Genomics Laboratories Inc., Laboratory Corporation of America Holdings, Bio-Reference Laboratories Inc., Abbott Laboratories are analyzed to be the key players of the prostate-specific antigen testing market. Quest Diagnostics provides services in sectors such as diagnostic testing, clinical trials testing, Healthcare IT, and wellness & risk management. Neo Genomics Laboratories provides services in diagnostics and pharma segments. Laboratory Corporation of America Holdings has made a partnership with Capital Health for implementing new services.
About IndustryARC:
IndustryARC is a research and consulting firm that publishes more than 500 reports annually in various industries, such as Agriculture, Automotive, Automation & Instrumentation, Chemicals and Materials, Energy and Power, Electronics, Food & Beverages, Information Technology, Life sciences & Healthcare.